CD19 and acute lymphoblastic leukemia: CAR T-cells that target the CD19 receptor on human leukemia and lymphoma cells have resulted in some impressive responses, and the FDA just approved the first CAR T-cell treatment for patients with CD19-positive acute lymphoblastic leukemia (ALL).1